Biogen, headquartered in Cambridge, Massachusetts, specializes in therapies for neurological diseases, employing 7,570 people and offering treatments for conditions like MS, SMA, Alzheimer's, and ALS. Their product portfolio includes TECFIDERA, SPINRAZA, and collaborations on LEQEMBI and others.
BIIB has been in the news recently: Biogen (BIIB) is set to announce its quarterly earnings report on July 31, 2025, which is important for investors. Additionally, the pharmaceutical industry may face challenges due to President Trump's proposed tariffs on imported drugs, affecting companies like AbbVie and Eli Lilly.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
